We wish to thank the editor and the reviewers for their encouraging and helpful comments regarding our article. Guided by their suggestions, we have now improved our manuscript and the revised version of the manuscript is being submitted. The changes in the manuscript are highlighted with yellow colour. A point-by-point explanation of the comment is appended below.

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: This review provides comprehensive information on therapeutic effect through known small molecules derived from synthetic or natural that can exert an agonism on PPARs. However, in the course of describing the nonclinical and/or clinical efficacy of all the presented agents, only their merits are highlighted. The therapeutic limitations of the agents (eg. druggability, resistance, adverse effect, and so on) must be indicated in each paragraph.

RESPONSE: Thanks for the invaluable suggestion. We have included the limitations of the agents in each paragraph as per the suggestion. The language of the manuscript is also polished using subscribed Grammarly software.

Reviewer #2:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: In this review, Swati Katoch et al summarized the recent progress in the role of PPAR γ as a therapeutic target for hepatocellular carcinoma, focusing on the various PPAR γ agonists. It is well-written with beautiful figures. I think it is very useful the specialists in this area.

RESPONSE: Thanks for the positive comments. The language of the manuscript is also polished using subscribed Grammarly software

Reviewer #3:

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: This review discussed the regulatory role of PPAR γ in HCC pathogenesis and experimental and clinical scenario PPAR γ agonist in HCC treatment. The content was novel and valuable. The article was well written and there were no obvious mistakes in the sentences.

RESPONSE: Thanks for the positive comments.

EDITORIAL OFFICE'S COMMENTS

(1) Science editor:

The manuscript reports the regulatory role of PPARy agonists in the pathogenesis of HCC and the experimental and clinical application of PPARy agonists in the treatment of HCC. The manuscript is well, concisely and coherently organized and presented and the style. Nevertheless, there are a number points that may deserve some revisions. The author can supplement the treatment limitations and adverse reactions of some drugs, and summarize the current clinical relevant process and case reports. В Language Quality: Grade (Minor language polishing) Scientific Quality: Grade C (Good)

RESPONSE: Thanks for the suggestions. The limitations of the agents are included in each paragraph as per the suggestion. The available reports on the clinical trials of PPAR gamma agonists against HCC are mentioned in Table 1 and also mentioned in the manuscript. The language of the manuscript is also polished using subscribed Grammarly software.

Company editor-in-chief:

I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastroenterology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please be sure to use Reference Citation Analysis (RCA) when revising the manuscript. RCA is an artificial intelligence technology-based open multidisciplinary citation analysis database. For details on the RCA, please visit the following web site: https://www.referencecitationanalysis.com/. Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file. Please authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom righthand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022. If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, "Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

RESPONSE: Revised the manuscript as per suggestions